1、该刊只有国际刊号！

2、投稿方式：在线投稿。

3、官网网址：

https://onlinelibrary.wiley.com/journal/26882663

（微信公众号信息）

4、投稿系统：https://mc.manuscriptcentral.com/medcomm

5、主办单位官网：https://www.scimea.cn/

（四川省国际医学交流促进会）

6、官网邮箱：

editorial@med-comm.org（编辑部）

review@med-comm.org（编辑部）

7、出刊日期：月刊，每月出版1期。

8、官方微信公众号：四川省国际医学交流促进会（scimea）

2025年3月10日星期一

MedComm简介

MedComm 是由中国科学院院士魏于全教授亲自操刀的又一优秀生物医学期刊。魏院士2016年创办的一流学术期刊Signal Transduction and Targeted Therapy（简称STTT），2020年影响因子18.187，位于SCI期刊JCR分区Q1区，全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。我们有理由相信MedComm 潜力无限，未来可期，成为高水平的国际期刊。

MedComm 是2020年由世界顶级出版集团Wiley出版的生物医学英文期刊（https://onlinelibrary.wiley.com/journal/26882663），目前已被ESCI、DOAJ、BIOSIS Previews等知名数据库收录，大部分论文PubMed也已收录。MedComm 竭诚欢迎生物医学领域的科研工作者、医生、研究生积极投稿。

MedComm 编委团队由英国牛津大学James Henderson Naismith教授（英国皇家科学院院士、英国皇家爱丁堡科学院院士）、耶鲁大学Günter P. Wagner教授（美国国家科学院院士、美国科学促进会院士、美国艺术与科学院院士）、川大华西医院生物治疗国家重点实验室魏于全教授（中国科学院院士）领导。编委团队由全球10多个国家的著名科学家构成，其中超过20%为国内外院士，60%以上为国外专家，包括宋伟宏院士、蒋华良院士、彭勇、黄灿华以及何明亮教授等著名专家教授。

创刊至今，MedComm 始终坚持高水平、国际化、严标准的办刊策略，所有刊载内容均经过严格的同行评审，专业高效的编辑团队管理，得到了国内外同行学者的广泛认可。MedComm 收到来自全球范围内顶尖大学和研究机构的高水平稿件。目前已在线发表80余篇论文，包括Biomaterials 主编Kam. W. Leong院士、英属哥伦比亚大学宋伟宏院士、南阿拉巴马大学Gary A. Piazza教授、多伦多大学Masoud Mozafari教授、哈佛医学院Wenjun Deng教授、美国圣约翰大学的陈哲生教授、天津医科大学姚智、第三军医大学叶丽林、浙江大学王福俤等国内外多位院士与教授的文章。MedComm 由衷地感谢期刊作者、审稿人、编辑和读者的巨大贡献, MedComm 将再接再厉，发表更多高质量的论文，更好地服务于全球的读者和作者。

《MedComm》投稿指南

【官网信息】

Author Guidelines

1. SUBMISSION

Authors

should kindly note that submission implies that the content has not

been published or submitted for publication elsewhere except as a brief

abstract in the proceedings of a scientific meeting or symposium.

Free Format submission

MedComm now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

Your

manuscript: this should be an editable file including text, figures,

and tables, or separate files – whichever you prefer. All required

sections should be contained in your manuscript, including abstract

(which does need to be correctly styled), introduction, methods,

results, and conclusions. Figures and tables should have legends.

Figures should be uploaded in the highest resolution possible. If the

figures are not of sufficiently high quality your manuscript may be

delayed. References may be submitted in any style or format, as long as

it is consistent throughout the manuscript. Supporting information

should be submitted in separate files. If the manuscript, figures or

tables are difficult for you to read, they will also be difficult for

the editors and reviewers, and the editorial office will send it back to

you for revision. Your manuscript may also be sent back to you for

revision if the quality of English language is poor.

An

ORCID ID, freely available at https://orcid.org. (Why is this

important? Your article, if accepted and published, will be attached to

your ORCID profile. Institutions and funders are increasingly requiring

authors to have ORCID IDs.)

The title page of the manuscript, including:

Your

co-author details, including affiliation and email address. (Why is

this important? We need to keep all co-authors informed of the outcome

of the peer review process.)

Statements

relating to our ethics and integrity policies, which may include any of

the following (Why are these important? We need to uphold rigorous

ethical standards for the research we consider for publication):

data availability statement

funding statement

conflict of interest disclosure

ethics approval statement

patient consent statement

permission to reproduce material from other sources

clinical trial registration

If

you are invited to revise your manuscript after peer review, the

journal will also request the revised manuscript to be formatted

according to journal requirements, see details in Section 4. Preparing

the Submission.

To

submit, login at https://mc.manuscriptcentral.com/medcomm and create a

new submission. Follow the submission steps as required and submit the

manuscript.

Click here for more details on how to use ScholarOne.

Data protection:

By

submitting a manuscript to or reviewing for this publication, your

name, email address, and affiliation, and other contact details the

publication might require, will be used for the regular operations of

the publication, including, when necessary, sharing with the publisher

(Wiley) and partners for production and publication. The publication and

the publisher recognize the importance of protecting the personal

information collected from users in the operation of these services, and

have practices in place to ensure that steps are taken to maintain the

security, integrity, and privacy of the personal data collected and

processed. You can learn more at

https://authorservices.wiley.com/statements/data-protection-policy.html.

Preprint policy:

Please find the Wiley preprint policy here.

This journal accepts article previously published on preprint servers.

MedComm

will consider for review articles previously available as preprints.

Authors are requested to update any pre-publication versions with a link

to the final published article. Authors may also post the final

published version of the article immediately after publication.

For help with submissions, please contact: editorial@med-comm.org or review@med-comm.org

2. AIMS AND SCOPE

MedComm

is a peer-reviewed, online open access journal that publishes the

pioneer works providing novel insights into all aspects of medicine on

the basis of novelty, timeliness and significance on human health. The

journal emphasizes on original findings that advances the understanding

of pathogenesis or improves the diagnosis and treatment of human

disease. Interdisciplinary studies utilizing approaches of molecular

biology, cell biology, chemistry, pharmacology or material science to

address the issues of clinical, basic and translational medicines are

particularly encouraged.

MedComm

is interested in the topics including but not limited to clinical

medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug

discovery, evolutionary medicine, nanotechnology or artificial

intelligence. Clinical and experimental advances that provide the

disease characteristics, pathogenic mechanism or medical techniques are

focused by the journal.

Topics of interest include, but are not limited to:

Epigenetics, genomics, proteomics and metabonomics

Non-coding RNA in disease

Cell senescence and cell death

Cellular signal transduction

Gene therapy and Gene editing

Cancer immunology and Immunotherapy

Structural Biology, chemical genomics and drug discovery

High-definition imaging

Artificial intelligence in medicine

Stem cells and Regenerative medicine

Nanomedicine and drug delivery system

Early disease diagnosis and biomarkers

Clinical trials evaluating new treatments for cancer or other diseases

……

更多详情：

https://onlinelibrary.wiley.com/page/journal/26882663/homepage/author-guidelines